Xie Duoli, Wang Zhuqian, Li Jie, Guo De-An, Lu Aiping, Liang Chao
Department of Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, China.
Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong SAR, China.
Front Oncol. 2022 Mar 4;12:843345. doi: 10.3389/fonc.2022.843345. eCollection 2022.
Since osteosarcoma (OS) is an aggressive bone cancer with unknown molecular pathways of etiology and pathophysiology, improving patient survival has long been a challenge. The conventional therapy is a complex multidisciplinary management that include radiotherapy, chemotherapy which followed by surgery and then post-operative adjuvant chemotherapy. However, they have severe side effects because the majority of the medicines used have just a minor selectivity for malignant tissue. As a result, treating tumor cells specifically without damaging healthy tissue is currently a primary goal in OS therapy. The coupling of chemotherapeutic drugs with targeting ligands is a unique therapy method for OS that, by active targeting, can overcome the aforementioned hurdles. This review focuses on advances in ligands and chemotherapeutic agents employed in targeted delivery to improve the capacity of active targeting and provide some insight into future therapeutic research for OS.
由于骨肉瘤（OS）是一种侵袭性骨癌，其病因和病理生理学的分子途径尚不清楚，长期以来提高患者生存率一直是一项挑战。传统疗法是一种复杂的多学科治疗，包括放疗、化疗，化疗后进行手术，然后是术后辅助化疗。然而，它们有严重的副作用，因为所用的大多数药物对恶性组织的选择性很小。因此，在不损害健康组织的情况下特异性治疗肿瘤细胞是目前骨肉瘤治疗的主要目标。将化疗药物与靶向配体偶联是一种独特的骨肉瘤治疗方法，通过主动靶向可以克服上述障碍。本文综述了用于靶向递送的配体和化疗药物的研究进展，以提高主动靶向能力，并为骨肉瘤未来的治疗研究提供一些见解。
